Investigational drug · Phase 3
non-immunogenic staphylokinase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ischemic Stroke, Acute.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "non-immunogenic staphylokinase"
First trial start
2026
Jun 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "non-immunogenic staphylokinase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ischemic Stroke, Acute
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "non-immunogenic staphylokinase" as an intervention, largest first.
Supergene, LLCIndustry
NCT06707987 · 23,250 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: Non-immunogenic staphylokinase · For: Acute Ischemic Stroke
Sites: Moscow, Russia
- Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary EmbolismRecruiting
Supergene, LLCIndustry
NCT07245927 · 20,000 participants (planned) · Start Jun 1, 2025 · Primary completion Oct 31, 2027
Drug: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin® · For: Pulmonary Embolism Acute Massive
Sites: Belgorod, Russia; Kemerovo, Russia; Kirov, Russia · 14 sites in all
- Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom OnsetPivotal-lookingRecruiting
Supergene, LLCIndustry
NCT07324837 · 1,050 participants (planned) · Start Jun 9, 2026 · Primary completion Nov 1, 2028
Drug: non-immunogenic staphylokinase; Placebo · For: Ischemic Stroke, Acute
Sites: Ryazan, Russia; Chelyabinsk, Russia; Irkutsk, Russia · 17 sites in all
- Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary EmbolismPivotal-lookingRecruiting
Supergene, LLCIndustry
NCT06362746 · 486 participants (planned) · Start May 23, 2024 · Primary completion Jun 1, 2028
Drug: Non-immunogenic recombinant staphylokinase; Placebo · For: Pulmonary Embolism
Sites: Barnaul, Russia; Vyselki, Russia; Asino, Russia · 24 sites in all
- Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPEPivotal-lookingCompleted
Supergene, LLCIndustry
NCT04688320 · 310 participants · Start Dec 15, 2020 · Primary completion Jul 27, 2023
Drug: Recombinant nonimmunogenic staphylokinase; Alteplase · For: Massive Pulmonary Embolism
Sites: Vyselki, Russia; Sergiyev Posad, Russia; Belgorod, Russia · 23 sites in all
- Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT TrialPivotal-lookingCompleted
Supergene, LLCIndustry
NCT05372718 · 170 participants · Start Dec 26, 2022 · Primary completion Sep 30, 2026
Drug: Recombinant non-immunogenic staphylokinase (Fortelyzin®) · For: Acute Limb Ischemia
Sites: Kursk, Russia; Sergiyev Posad, Russia; Kaliningrad, Russia · 8 sites in all
- Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF TrialPivotal-lookingTerminated
Supergene, LLCIndustry
NCT05135546 · 4 participants · Start Dec 27, 2021 · Primary completion Feb 1, 2023
Drug: Recombinant nonimmunogenic staphylokinase; Placebo · For: COVID-19
Sites: Moscow, Russia · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients agedߙࣙߙ60 years with acute ischemic stroke by THRIVE scale.
Shamalov NA, Chefranova ZY, Yarovaya EB, et al. · J Thromb Thrombolysis 2026
- Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study.
Shamalov NA, Martynov MY, Yarovaya EB, et al. · Stroke 2026
- [Thrombolytic therapy with non-immunogenic staphylokinase in an extended therapeutic window for ischemic stroke. (A single-center experience)].
Kazakov DN, Demin DA, Davletov VS, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2026
- [Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry].
Shamalov NA, Martynov MY, Gusev EI, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2026
- [Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT].
Zatevakhin II, Chupin AV, Karpenko AA, et al. · Angiol Sosud Khir 2025
- The Safety of Non-immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE.
Leontyev SG, Yarovaya EB, Kutsenko VA, et al. · Health Sci Rep 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.